v3.26.3
Stockholders' equity (Tables)
6 Months Ended
Sep. 30, 2026
Stockholders’ equity [Abstract]  
Summary of Company's Outstanding Warrants Exercisable for Shares of Common Stock
The following table summarizes the Company’s outstanding warrants as of September 30, 2026, all of which are exercisable for shares of Common Stock:
 
                
September 30, 2026
    No. of
warrants
    Exercise
Price ($)
    Expiration
Date
 
Equity classified warrants
              
Pre-funded warrants issued in connection with September 2023 private placement
  338,252    0.0001    
No expiration
 
Common warrants issued in connection with February 2025 private placement
  4,418,292    3.395    (1) 
Pre-funded warrants issued in connection with February 2025 private placement
  657,708    0.0001    
No expiration
 
 
1)
The February 2025 common warrants will expire on the earlier of: (i) the 60th day after the date the FDA approves the NDA for GTx-104 and (ii) September 25, 2028.